Knowledge Center
Topic
Clear
Close
When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?
Podcast: The Customer Experience Journey
Teva api Adopts New Nitrosamine Regulations
Navigating China’s API Regulations
Creatively using co-crystals to produce alternative generic products
Teva api Offers New API Sterilization Services
EcoVadis assessment
A global API supplier that understands the API industry!
Latest site inspections
- Feb 17-21, 2020 Teva API had a successful inspection in the Teva api Italy, Rho site by AIFA
- Feb 11-14, 2020 Teva API had a successful inspection in the Teva api India, Malanpur site by PMDA
- Jan 20-24, 2020 Teva API had a successful inspection in the Teva api Croatia site by USFDA
Latest regulatory updates
- Jun 13, 2021 CEP
- May 01, 2021 EU DMF
- Nov 29, 2020 US DMF